Our client is an innovative biotech firm. It's really a research think-tank developing new therapeutic platforms. Its innovation process starts with large unmet medical needs, and solutions are custom-designed by conceptualizing and executing genuinely novel ways to address them; this process allows consideration of all potential routes, including some that might not have been tried before, as the process is not linked to any specific background model, technology or university.
Its core area of expertise is Regenerative Medicine R&D, in particular the direct cell reprogramming approach to this field. Lead technologies, including stem cells, biomaterials and drugs have been developed over the past 10+ years and are under full IP protection.
For example, our client received the first patent in the USA for directly reprogrammed cells, a technology allowing the production of precursor cells (e.g. neural, cardiac, hematopoietic) directly from other somatic cells. He developed biomaterial that speeds the regeneration of central nervous system cells and soft tissues while inhibiting tumor growth, while their cell regeneration drug program has led to the development of a drug that not only prevents the cell or tissue loss resulting from neurodegenerative diseases such as multiple sclerosis and Parkinson’s disease, brain and spinal cord injuries, stroke and diabetes, etc., but also has indirect regenerative effects on tissues.
Position based in Montreal.
The challenge ------
You will be working with direct reprogramming of human somatic cells into various types of multipotent and unipotent precursor cells.
Cell culturing is done without antibiotics in a cleanroom-level lab. You will also be analyzing these cells on various robotic and analytical machines; thus, you need to feel comfortable analyzing this quantitative data to aid in your decision-making process for the next step.
You will be part of a progressive team helping to make and design the next generation of cell therapeutics.
The missions ------
About you ------